山东大学耳鼻喉眼学报 ›› 2022, Vol. 36 ›› Issue (2): 40-44.doi: 10.6040/j.issn.1673-3770.0.2021.368
程瑶1,张震1,杨吉2,冯成敏1,邓启成1,张西1,赵锐1,朱鑫1,吴俊志1,刘海1,邓世山3
CHENG Yao1, ZHANG Zhen1, YANG Ji2, FENG Chengmin1, DENG Qicheng1, ZHANG Xi1, ZHAO Rui1, ZHU Xin1, WU Junzhi1, LIU Hai1, DENG Shishan3
摘要: 目的 探讨下咽癌组织中蛋白磷酸酶2A的癌性抑制因子(CIP2A)的表达与患者临床病理特征和预后的关系。 方法 于川北医学院附属医院病理科收集2016年1月至2020年12月下咽癌组织标本共58例,其中配对癌旁组织标本20例,同时选取30例正常下咽组织纳入分析。 结果 免疫组化SP显示,CIP2A在下咽癌组织中的表达水平显著高于在癌旁及正常下咽组织中的表达水平(P<0.001)。CIP2A的表达与患者是否饮酒、病理分化程度、临床分期、是否有淋巴结转移有明显关系(P<0.05),而与性别、年龄、是否吸烟、临床分型无明显关系。单因素Log-rank检验分析显示患者年龄、临床分期、CIP2A表达与患者预后相关(P<0.05)。进一步Cox风险比例回归模型分析发现CIP2A表达是影响下咽癌预后的独立危险因素。 结论 蛋白磷酸酶2A的癌性抑制因子CIP2A在下咽癌组织中异常表达提示其可能参与了肿瘤的发生发展,CIP2A高表达的下咽癌患者预后较差,故CIP2A有望成为下咽癌患者诊断、治疗与预后的分子标志物之一。
中图分类号:
[1] Garneau JC, Bakst RL, Miles BA. Hypopharyngeal cancer: a state of the art review[J]. Oral Oncol, 2018, 86: 244-250. doi:10.1016/j.oraloncology.2018.09.025. [2] Kwon DI, Miles BA. Hypopharyngeal carcinoma: do You know your guidelines? [J]. Head Neck, 2019, 41(3): 569-576. doi:10.1002/hed.24752. [3] Hall SF, Groome PA, Irish J, et al. The natural history of patients with squamous cell carcinoma of the hypopharynx[J]. Laryngoscope, 2008, 118(8): 1362-1371. doi:10.1097/MLG.0b013e318173dc4a. [4] Newman JR, Connolly TM, Illing EA, et al. Survival trends in hypopharyngeal cancer: a population-based review[J]. Laryngoscope, 2015, 125(3): 624-629. doi:10.1002/lary.24915. [5] Soo Hoo L, Zhang JY, Chan EKL. Cloning and characterization of a novel 90 kDa ‘companion’ auto-antigen of p62 overexpressed in cancer[J]. Oncogene, 2002, 21(32): 5006-5015. doi:10.1038/sj.onc.1205625. [6] Junttila MR, Puustinen P, Niemelä M, et al. CIP2A inhibits PP2A in human malignancies[J]. Cell, 2007, 130(1): 51-62. doi:10.1016/j.cell.2007.04.044. [7] Christophe Côme, Anni Laine, Maïa Chanrion, et al. CIP2A has been associated with the aggressiveness of breast cancer in humans[J]. Clin Cancer Res, 2009,15(16): 5092-5100. doi:10.1158/1078-0432.CCR-08-3283. [8] Xue YJ, Wu GQ, Wang XN, et al. CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma[J]. Med Oncol, 2013, 30(1): 406. doi:10.1007/s12032-012-0406-6. [9] Liu XW, Duan C, Ji JL, et al. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells[J]. Oncol Rep, 2017, 38(1): 271-278. doi:10.3892/or.2017.5648. [10] Yu GZ, Liu GH, Dong J, et al. Clinical implications of CIP2A protein expression in breast cancer[J]. Med Oncol, 2013, 30(2): 524. doi:10.1007/s12032-013-0524-9. [11] Cristóbal I, Zazo S, Torrejón B, et al. CIP2A confirms its prognostic value in triple-negative breast cancer[J]. Oncogene, 2017, 36(23): 3357-3358. doi:10.1038/onc.2016.474. [12] Vaarala MH, Väisänen MR, Ristimäki A. CIP2A expression is increased in prostate cancer[J]. J Exp Clin Cancer Res, 2010, 29(1): 136. doi:10.1186/1756-9966-29-136. [13] Cristóbal I, Rojo F, Madoz-Gúrpide J, et al. Cross talk between Wnt/β-catenin and CIP2A/Plk1 signaling in prostate cancer: promising therapeutic implications[J]. Mol Cell Biol, 2016, 36(12): 1734-1739. doi:10.1128/mcb.00130-16. [14] Peng B, Chai YR, Li Y, et al. CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer[J]. BMC Cancer, 2015, 15: 895. doi:10.1186/s12885-015-1899-0. [15] Chao TT, Maa HC, Wang CY, et al. CIP2A is a poor prognostic factor and can be a diagnostic marker in papillary thyroid carcinoma[J]. APMIS, 2016, 124(12): 1031-1037. doi:10.1111/apm.12602. [16] 莫海兰, 李洁, 杨智玲, 等. CIP2A在喉癌组织中的表达及其临床意义[J]. 第三军医大学学报, 2012, 34(16): 1663-1667. doi:10.16016/j.1000-5404.2012.16.032. MO Hailan, LI Jie, YANG Zhiling, et al. Expression of CIP2A in laryngeal squamous cell carcinoma and its clinical significance[J]. Journal of Third Military Medical University, 2012, 34(16): 1663-1667. doi:10.16016/j.1000-5404.2012.16.032. [17] Eckel HE, Bradley PJ. Natural history of treated and untreated hypopharyngeal cancer[J]. Adv Otorhinolaryngol, 2019, 83: 27-34. doi:10.1159/000492305. [18] 潘新良, 魏东敏. 正确认识 科学评估 积极推进下咽癌规范治疗[J]. 中华耳鼻咽喉头颈外科杂志, 2020, 55(12): 1116-1119. doi:10.3760/cma.j.cn115330-20201004-00785. PAN Xinliang, WEI Dongmin. Correctly understanding, scientifically evaluating, and actively promoting standardized treatment of hypopharyngeal cancer[J]. Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2020, 55(12):1116-1119. doi:10.3760/cma.j.cn115330-20201004-00785. [19] Mathiasen DP, Egebjerg C, Andersen SH, et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation[J]. Oncogene, 2012, 31(3): 390-401. doi:10.1038/onc.2011.230. [20] Kerosuo L, Fox H, Perälä N, et al. CIP2A increases self-renewal and is linked to Myc in neural progenitor cells[J]. Differentiation, 2010, 80(1): 68-77. doi:10.1016/j.diff.2010.04.003. [21] Laine A, Sihto H, Come C, et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1[J]. Cancer Discov, 2013, 3(2): 182-197. doi:10.1158/2159-8290.CD-12-0292. [22] Khanna A, Pimanda JE, Westermarck J. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target[J]. Cancer Res, 2013, 73(22): 6548-6553. doi:10.1158/0008-5472.CAN-13-1994. [23] Côme C, Laine A, Chanrion M, et al. CIP2A is associated with human breast cancer aggressivity[J]. Clin Cancer Res, 2009, 15(16): 5092-5100. doi:10.1158/1078-0432.CCR-08-3283. [24] Laine A, Nagelli SG, Farrington C, et al. CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis[J]. Cancer Res, 2021, 81(16): 4319-4331. doi:10.1158/0008-5472.CAN-20-3651. [25] Ventelä S, Côme C, Mäkelä JA, et al. CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice[J]. PLoS One, 2012, 7(3): e33209. doi:10.1371/journal.pone.0033209. |
[1] | 陈东彦,钱晔,魏东敏,李文明,夏同良,雷大鹏,潘新良. 高频超声诊断下咽鳞癌淋巴结转移的临床研究[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 18-23. |
[2] | 姜超,周炫辰,韩杰,岳志勇. IVc期下咽癌特征分析及列线图预后模型构建[J]. 山东大学耳鼻喉眼学报, 2022, 36(4): 49-54. |
[3] | 冯成敏,敬一丹刘海,王冰. 咽喉部鳞状细胞癌细胞系[J]. 山东大学耳鼻喉眼学报, 2021, 35(6): 113-124. |
[4] | 刘盼,王川,赵泽祺,吴梅,徐继峰,李巍,张伟强,刘稳. 头颈部转移性透明细胞癌5例并文献复习[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 45-50. |
[5] | 王中卫,杨林,郭亚,孙斌,王亚利,马秀龙,任宏涛,包兴. 鼻咽癌患者miR-429、miR-200C表达与预后关系分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 81-86. |
[6] | 王莹莹,周涵,董伟达,邢光前,陈智斌,张清照,张立庆. 外耳道腺样囊性癌的远处转移及预后分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 1-6. |
[7] | 谭玉芳,易天华. 鼻咽癌放疗后突发性聋18例[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 35-39. |
[8] | 王亚越, 孙娟. 下咽癌中差异表达的蛋白激酶及抑制剂的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 119-124. |
[9] | 崔小缓,李丽娜,张延平,蒋兴旺,毕欣欣,冉桃桃,吴莹莹,刘雅莉. 改良负压封闭引流装置在难治性咽瘘治疗中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 49-53. |
[10] | 黄俊伟,陈学军,刘宏飞,陶冶,李祖飞,陈平,张洋. 细胞周期蛋白E2在下咽癌中的表达及其意义[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 132-137. |
[11] | 周芳茗,谢艳,刘洋蒋路云. 鼻源性头痛的研究动态分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 130-133. |
[12] | 徐进敬,胡京华,吴元庆,邓毅,喻唯唯. CO2激光显微手术在喉癌前病变和早期声门型喉癌中的应用[J]. 山东大学耳鼻喉眼学报, 2020, 34(3): 129-133. |
[13] | 陈慧君,宋圣花,董伟达,周涵. 术前外周血纤维蛋白原水平对喉癌预后的影响[J]. 山东大学耳鼻喉眼学报, 2020, 34(2): 110-114. |
[14] | 丁玉静,兰兰,王秋菊,冀飞,熊芬,谢林怡,丁海娜,夏寅,赵辉. 外伤导致听力损失的临床特点及预后[J]. 山东大学耳鼻喉眼学报, 2020, 34(1): 9-14. |
[15] | 宗小芳,胡国华,钟时勋,雷艳,江黎珠,康厚墉. 影响低频下降型突发性聋不伴眩晕预后的相关因素分析[J]. 山东大学耳鼻喉眼学报, 2020, 34(1): 33-37. |
|